These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37509701)

  • 1. Heterozygous Pathogenic Nonsense Variant in the
    Guadagnolo D; Mastromoro G; Marchionni E; Germani A; Libi F; Sadeghi S; Savio C; Petrucci S; De Marchis L; Piane M; Pizzuti A
    Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients.
    Gervas P; Molokov A; Ivanova A; Panferova Y; Kiselev A; Chernyshova A; Pisareva L; Choynzonov E; Cherdyntseva N
    Exp Oncol; 2021 Mar; 43(1):52-55. PubMed ID: 33785725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women.
    Kurian AW; Hughes E; Handorf EA; Gutin A; Allen B; Hartman AR; Hall MJ
    JCO Precis Oncol; 2017 Nov; 1():1-12. PubMed ID: 35172496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High frequency of pathogenic non-founder germline mutations in
    Maksimenko J; Irmejs A; Trofimovičs G; Bērziņa D; Skuja E; Purkalne G; Miklaševičs E; Gardovskis J
    Hered Cancer Clin Pract; 2018; 16():12. PubMed ID: 29928469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New germline BRCA2 gene variant in the Tuvinian Mongol breast cancer patients.
    Gervas P; Klyuch B; Denisov E; Kiselev A; Molokov A; Pisareva L; Malinovskaya E; Choynzonov E; Cherdyntseva N
    Mol Biol Rep; 2019 Oct; 46(5):5537-5541. PubMed ID: 31273614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
    Kurian AW; Ward KC; Abrahamse P; Bondarenko I; Hamilton AS; Deapen D; Morrow M; Berek JS; Hofer TP; Katz SJ
    J Clin Oncol; 2021 May; 39(15):1631-1640. PubMed ID: 33560870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
    Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
    Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic Cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation.
    Vietri MT; D'Elia G; Caliendo G; Albanese L; Signoriello G; Napoli C; Molinari AM
    Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study.
    Li W; Shao D; Li L; Wu M; Ma S; Tan X; Zhong S; Guo F; Wang Z; Ye M
    J Ovarian Res; 2019 Aug; 12(1):80. PubMed ID: 31472684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenicity Reclassification of Genetic Variants Related to Early-Onset Breast Cancer among Women of Mongoloid Origin.
    Gervas P; Molokov A; Babyshkina N; Kiselev A; Zarubin A; Yumov E; Pisareva L; Choynzonov E; Cherdyntseva N
    Asian Pac J Cancer Prev; 2022 Jun; 23(6):2027-2033. PubMed ID: 35763645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating the prevalence of pathogenic variants in Saudi Arabian patients with familial cancer using a multigene next generation sequencing panel.
    AlHarbi M; Mobark NA; AlJabarat WAR; ElBardis H; AlSolme E; Hamdan AB; AlFakeeh AH; AlMushawah F; AlHarthi F; AlSharm AA; Balbaid AAO; AlJohani N; Zhou AY; Robinson HA; Alqahtani SA; Abedalthagafi M
    Oncotarget; 2023 Jun; 14():580-594. PubMed ID: 37306523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
    Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
    Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families.
    Li J; Meeks H; Feng BJ; Healey S; Thorne H; Makunin I; Ellis J; ; Campbell I; Southey M; Mitchell G; Clouston D; Kirk J; Goldgar D; Chenevix-Trench G
    J Med Genet; 2016 Jan; 53(1):34-42. PubMed ID: 26534844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.
    Foretová L; Navrátilová M; Svoboda M; Vašíčková P; Sťahlová EH; Házová J; Kleiblová P; Kleibl Z; Macháčková E; Palácová M; Petráková K
    Klin Onkol; 2019; 32(Supplementum2):6-13. PubMed ID: 31409076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Perspectives on the Recurrent Monoallelic Germline Mutations of DNA Repair and Checkpoint Genes and Clinical Variability.
    Sahin I; Saat H
    Genet Test Mol Biomarkers; 2022 Jan; 26(1):17-25. PubMed ID: 35089076
    [No Abstract]   [Full Text] [Related]  

  • 17. Detection of Germline Variants in 450 Breast/Ovarian Cancer Families with a Multi-Gene Panel Including Coding and Regulatory Regions.
    Guglielmi C; Scarpitta R; Gambino G; Conti E; Bellè F; Tancredi M; Cervelli T; Falaschi E; Cosini C; Aretini P; Congregati C; Marino M; Patruno M; Pilato B; Spina F; Balestrino L; Tenedini E; Carnevali I; Cortesi L; Tagliafico E; Tibiletti MG; Tommasi S; Ghilli M; Vivanet C; Galli A; Caligo MA
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
    Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
    JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception.
    Bychkovsky BL; Lo MT; Yussuf A; Horton C; Hemyari P; LaDuca H; Garber JE; Scheib R; Rana HQ
    Breast Cancer Res Treat; 2023 Jul; 200(1):63-72. PubMed ID: 36856935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and spectrum of pathogenic variants among patients with multiple primary cancers evaluated by clinical characteristics.
    Bychkovsky BL; Lo MT; Yussuf A; Horton C; Richardson M; LaDuca H; Garber JE; Rana HQ
    Cancer; 2022 Mar; 128(6):1275-1283. PubMed ID: 34875721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.